Rates of Serious Infections in HIV-Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases

Sintawat Wangsiricharoen, Colin Ligon, Lydia Gedmintas, Admad Dehrab, Marisa Tungsiripat, Clifton Bingham, Carlos Lozada, Leonard Calabrese

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: To estimate the incidence of serious infections in patients with HIV infection and autoimmune disease who were treated with tumor necrosis factor (TNF) inhibitors, and to compare these rates by stratified viral load levels. Methods: Using a unified search strategy, 4 centers identified HIV-infected patients exposed to TNF inhibitors. Patient characteristics and infection data were assessed via chart review in all patients who were ≥18 years old and who received TNF inhibitor therapy after HIV diagnosis, between January 1999 and March 2015. Results: We studied 23 patients with 26 uses of TNF inhibitor therapy (86.7 person-years of followup). Two (8.7%) experienced at least 1 serious infection episode, for an overall incidence rate of 2.55 per 100 patient-years (95% confidence interval [95% CI] 0.28–9.23). The incidence rate per 100 patient-years was 3.28 (95% CI 0.04–18.26) among patients with a viral load >500 copies/ml at therapy initiation and 2.09 (0.03–11.65) among patients with a viral load ≤500 copies/ml. Conclusion: This study suggests that the rate of serious infections in patients with HIV infection under active care who have received treatment with TNF inhibitors may be comparable to the rates observed in registry databases.

Original languageEnglish (US)
Pages (from-to)449-452
Number of pages4
JournalArthritis Care and Research
Volume69
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Autoimmune Diseases
HIV Infections
Tumor Necrosis Factor-alpha
Viral Load
Therapeutics
Infection
Incidence
HIV
Confidence Intervals
Registries
Databases

ASJC Scopus subject areas

  • Rheumatology

Cite this

Wangsiricharoen, S., Ligon, C., Gedmintas, L., Dehrab, A., Tungsiripat, M., Bingham, C., ... Calabrese, L. (2017). Rates of Serious Infections in HIV-Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases. Arthritis Care and Research, 69(3), 449-452. https://doi.org/10.1002/acr.22955

Rates of Serious Infections in HIV-Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases. / Wangsiricharoen, Sintawat; Ligon, Colin; Gedmintas, Lydia; Dehrab, Admad; Tungsiripat, Marisa; Bingham, Clifton; Lozada, Carlos; Calabrese, Leonard.

In: Arthritis Care and Research, Vol. 69, No. 3, 01.03.2017, p. 449-452.

Research output: Contribution to journalArticle

Wangsiricharoen, Sintawat ; Ligon, Colin ; Gedmintas, Lydia ; Dehrab, Admad ; Tungsiripat, Marisa ; Bingham, Clifton ; Lozada, Carlos ; Calabrese, Leonard. / Rates of Serious Infections in HIV-Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases. In: Arthritis Care and Research. 2017 ; Vol. 69, No. 3. pp. 449-452.
@article{d52812547f114848ab870eb3c3ad63fa,
title = "Rates of Serious Infections in HIV-Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases",
abstract = "Objective: To estimate the incidence of serious infections in patients with HIV infection and autoimmune disease who were treated with tumor necrosis factor (TNF) inhibitors, and to compare these rates by stratified viral load levels. Methods: Using a unified search strategy, 4 centers identified HIV-infected patients exposed to TNF inhibitors. Patient characteristics and infection data were assessed via chart review in all patients who were ≥18 years old and who received TNF inhibitor therapy after HIV diagnosis, between January 1999 and March 2015. Results: We studied 23 patients with 26 uses of TNF inhibitor therapy (86.7 person-years of followup). Two (8.7{\%}) experienced at least 1 serious infection episode, for an overall incidence rate of 2.55 per 100 patient-years (95{\%} confidence interval [95{\%} CI] 0.28–9.23). The incidence rate per 100 patient-years was 3.28 (95{\%} CI 0.04–18.26) among patients with a viral load >500 copies/ml at therapy initiation and 2.09 (0.03–11.65) among patients with a viral load ≤500 copies/ml. Conclusion: This study suggests that the rate of serious infections in patients with HIV infection under active care who have received treatment with TNF inhibitors may be comparable to the rates observed in registry databases.",
author = "Sintawat Wangsiricharoen and Colin Ligon and Lydia Gedmintas and Admad Dehrab and Marisa Tungsiripat and Clifton Bingham and Carlos Lozada and Leonard Calabrese",
year = "2017",
month = "3",
day = "1",
doi = "10.1002/acr.22955",
language = "English (US)",
volume = "69",
pages = "449--452",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Rates of Serious Infections in HIV-Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases

AU - Wangsiricharoen, Sintawat

AU - Ligon, Colin

AU - Gedmintas, Lydia

AU - Dehrab, Admad

AU - Tungsiripat, Marisa

AU - Bingham, Clifton

AU - Lozada, Carlos

AU - Calabrese, Leonard

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Objective: To estimate the incidence of serious infections in patients with HIV infection and autoimmune disease who were treated with tumor necrosis factor (TNF) inhibitors, and to compare these rates by stratified viral load levels. Methods: Using a unified search strategy, 4 centers identified HIV-infected patients exposed to TNF inhibitors. Patient characteristics and infection data were assessed via chart review in all patients who were ≥18 years old and who received TNF inhibitor therapy after HIV diagnosis, between January 1999 and March 2015. Results: We studied 23 patients with 26 uses of TNF inhibitor therapy (86.7 person-years of followup). Two (8.7%) experienced at least 1 serious infection episode, for an overall incidence rate of 2.55 per 100 patient-years (95% confidence interval [95% CI] 0.28–9.23). The incidence rate per 100 patient-years was 3.28 (95% CI 0.04–18.26) among patients with a viral load >500 copies/ml at therapy initiation and 2.09 (0.03–11.65) among patients with a viral load ≤500 copies/ml. Conclusion: This study suggests that the rate of serious infections in patients with HIV infection under active care who have received treatment with TNF inhibitors may be comparable to the rates observed in registry databases.

AB - Objective: To estimate the incidence of serious infections in patients with HIV infection and autoimmune disease who were treated with tumor necrosis factor (TNF) inhibitors, and to compare these rates by stratified viral load levels. Methods: Using a unified search strategy, 4 centers identified HIV-infected patients exposed to TNF inhibitors. Patient characteristics and infection data were assessed via chart review in all patients who were ≥18 years old and who received TNF inhibitor therapy after HIV diagnosis, between January 1999 and March 2015. Results: We studied 23 patients with 26 uses of TNF inhibitor therapy (86.7 person-years of followup). Two (8.7%) experienced at least 1 serious infection episode, for an overall incidence rate of 2.55 per 100 patient-years (95% confidence interval [95% CI] 0.28–9.23). The incidence rate per 100 patient-years was 3.28 (95% CI 0.04–18.26) among patients with a viral load >500 copies/ml at therapy initiation and 2.09 (0.03–11.65) among patients with a viral load ≤500 copies/ml. Conclusion: This study suggests that the rate of serious infections in patients with HIV infection under active care who have received treatment with TNF inhibitors may be comparable to the rates observed in registry databases.

UR - http://www.scopus.com/inward/record.url?scp=85013893735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013893735&partnerID=8YFLogxK

U2 - 10.1002/acr.22955

DO - 10.1002/acr.22955

M3 - Article

C2 - 27332039

AN - SCOPUS:85013893735

VL - 69

SP - 449

EP - 452

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 3

ER -